{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:50:50Z","timestamp":1794556250019,"version":"4.9.1"},"reference-count":118,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Basic Science Research Program through the National Research Foundation (NRF) of Korea"},{"name":"Ministry of Education","award":["2021R1I1A3056261"],"award-info":[{"award-number":["2021R1I1A3056261"]}]},{"name":"KRIBB Research Initiative Program"},{"name":"Jeonbuk RISE Center"},{"name":"Ministry of Education (MOE) and the Jeonbuk State, Republic of Korea","award":["2025-RISE-13-WSU"],"award-info":[{"award-number":["2025-RISE-13-WSU"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors are widely used in type 2 diabetes and cardiometabolic diseases, and their pharmacokinetic characteristics generally confer a low risk of clinically relevant drug\u2013drug interactions (DDIs). Most clinical studies demonstrate that these agents can be co-administered safely with commonly prescribed medications without dose adjustment, although strong enzyme inducers such as rifampin can reduce systemic exposure, and pharmacodynamic interactions may still arise. However, existing evidence is largely derived from short-term studies in healthy volunteers, with limited data in special populations and minimal evaluation of metabolite- or transporter-mediated interactions. This review summarizes the available in vitro and in vivo pharmacokinetic and DDI data for SGLT2 inhibitors, identifies key knowledge gaps related to polypharmacy, metabolite effects, and vulnerable patient groups, and outlines future research priorities to ensure their safe and effective use in real-world clinical practice.<\/jats:p>","DOI":"10.3390\/pharmaceutics17121604","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:19:02Z","timestamp":1765556342000},"page":"1604","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacokinetic Landscape and Interaction Potential of SGLT2 Inhibitors: Bridging In Vitro Findings and Clinical Implications"],"prefix":"10.3390","volume":"17","author":[{"given":"Nahyun","family":"Koo","sequence":"first","affiliation":[{"name":"College of Pharmacy, Woosuk University, Wanju 55338, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ji","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Woosuk University, Wanju 55338, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Eun","family":"Chang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dongduk Women\u2019s University, Seoul 02748, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2175-8876","authenticated-orcid":false,"given":"Kyeong-Ryoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Republic of Korea"},{"name":"Department of Biotechnology, University of Science and Technology, Daejeon 34113, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-4192","authenticated-orcid":false,"given":"Yoon-Jee","family":"Chae","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Woosuk University, Wanju 55338, Republic of Korea"},{"name":"Research Institute of Pharmaceutical Sciences, Woosuk University, Wanju 55338, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/met.2023.0006","article-title":"The Bidirectional Association of Chronic Kidney Disease, Type 2 Diabetes, Atherosclerotic Cardiovascular Disease, and Heart Failure: The Cardio\u2013Renal\u2013Metabolic Syndrome","volume":"21","author":"Nichols","year":"2023","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41591-018-0159-7","article-title":"Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase","volume":"24","author":"Hunter","year":"2018","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","article-title":"Metformin: Update on mechanisms of action and repurposing potential","volume":"19","author":"Foretz","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.15663","article-title":"Metformin: Therapeutic profile in the treatment of type 2 diabetes","volume":"26","author":"Bailey","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_6","first-page":"936","article-title":"The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus","volume":"9","author":"Prioletta","year":"2013","journal-title":"Arch. Med. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e000327","DOI":"10.1136\/openhrt-2015-000327","article-title":"Acarbose: Safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes","volume":"2","author":"DiNicolantonio","year":"2015","journal-title":"Open Heart"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.7570\/jomes.2017.26.2.102","article-title":"Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health?","volume":"26","author":"Ko","year":"2017","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ahr\u00e9n, B. (2019). DPP-4 inhibition and the path to clinical proof. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00376"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e240046","DOI":"10.1530\/JOE-24-0046","article-title":"GLP-1 receptor agonist-based therapies and cardiovascular risk: A review of mechanisms","volume":"263","author":"Mullur","year":"2024","journal-title":"J. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition-a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.20945\/2359-3997000000440","article-title":"Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"66","author":"Pinto","year":"2022","journal-title":"Arch. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"A58","DOI":"10.1186\/1758-5996-7-S1-A58","article-title":"Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: A systematic review and meta-analysis","volume":"7","author":"Pinto","year":"2015","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/00325481.2018.1423852","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"130","author":"Guthrie","year":"2018","journal-title":"Postgrad. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101428","DOI":"10.37349\/eemd.2025.101428","article-title":"Updates from the 2025 American Diabetes Association guidelines on standards of medical care in diabetes","volume":"2","author":"Tiwari","year":"2025","journal-title":"Explor. Endocr. Metab. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/ehjqcco\/qcae105","article-title":"Key priorities for the implementation of the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes in low-resource settings","volume":"11","author":"Marx","year":"2025","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"154218","DOI":"10.1016\/j.metabol.2020.154218","article-title":"New American Diabetes Association (ADA)\/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician\u2019s perspective","volume":"107","author":"Katsiki","year":"2020","journal-title":"Metab. Clin. Exp."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gallwitz, B. (2019). Clinical Use of DPP-4 Inhibitors. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00389"},{"key":"ref_24","unstructured":"United States Food and Drug Administration (2025, May 02). Prescribing Information of Invokana (Canagliflozin), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/204042s043lbl.pdf."},{"key":"ref_25","unstructured":"(2025, May 02). Prescribing Information of Farxiga (Dapagliflozin), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/202293s031lbl.pdf."},{"key":"ref_26","unstructured":"(2025, May 02). Prescribing Information of Jardiance (Empagliflozin), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/204629s040lbl.pdf."},{"key":"ref_27","unstructured":"(2025, May 02). Prescribing Information of Steglatro (Ertugliflozin), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/209803s008lbledt.pdf."},{"key":"ref_28","unstructured":"(2025, May 02). Prescribing Information of Brenzavvy (Bexagliflozin), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/214373s001lbl.pdf."},{"key":"ref_29","unstructured":"(2025, May 02). Prescribing Information of Inpefa (Sotagliflozin), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216203s000lbl.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40265-014-0204-x","article-title":"Ipragliflozin: First global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s40265-014-0230-8","article-title":"Luseogliflozin: First global approval","volume":"74","author":"Markham","year":"2014","journal-title":"Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40265-014-0229-1","article-title":"Tofogliflozin: First global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40265-019-01150-9","article-title":"Remogliflozin etabonate: First global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/dom.14926","article-title":"Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Gao","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.clinthera.2020.12.012","article-title":"Tolerability, pharmacokinetic, and pharmacodynamic profiles of henagliflozin, a novel selective inhibitor of sodium-glucose cotransporter 2, in healthy subjects following single-and multiple-dose administration","volume":"43","author":"Zhang","year":"2021","journal-title":"Clin. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/00325481.2018.1394152","article-title":"SGLT2 inhibitors: Are they safe?","volume":"130","author":"Filippatos","year":"2018","journal-title":"Postgrad. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4103\/ijem.IJEM_159_17","article-title":"Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus","volume":"22","author":"Unnikrishnan","year":"2018","journal-title":"Indian. J. Endocrinol. Metab."},{"key":"ref_38","first-page":"783","article-title":"Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: A meta-analysis of randomized clinical trials","volume":"18","author":"Bazoukis","year":"2021","journal-title":"J. Geriatr. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41574-019-0275-6","article-title":"SGLT2 inhibitors and urinary tract infections","volume":"15","author":"Wilding","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_40","unstructured":"(2025, May 02). FDA Drug Safety Communication:FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings About Too Much Acid in the Blood and Serious Urinary Tract Infections, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious."},{"key":"ref_41","unstructured":"(2025, May 02). SGLT2 Inhibitors\u2014Referral 2016. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/sglt2-inhibitors."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/bcp.13186","article-title":"In vitro and physiologically-based pharmacokinetic based assessment of drug\u2013drug interaction potential of canagliflozin","volume":"83","author":"Mamidi","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_43","unstructured":"FDA Center for Drug Evaluation and Research (2025, May 20). Clinical Pharmacology and Biopharmaceutics Review (Canagliflozin), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204042Orig1s000ClinPharmR.pdf."},{"key":"ref_44","unstructured":"FDA Center for Drug Evaluation and Research (2025, May 20). Clinical Pharmacology and Biopharmaceutics Review (Dapagliflozin), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/202293Orig1s000ClinPharmR.pdf."},{"key":"ref_45","unstructured":"FDA Center for Drug Evaluation and Research (2025, May 20). Clinical Pharmacology and Biopharmaceutics Review (Empagliflozin), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/204629Orig1s000ClinPharmR.pdf."},{"key":"ref_46","unstructured":"FDA Center for Drug Evaluation and Research (2025, May 20). Clinical Pharmacology and Biopharmaceutics Review (Ertugliflozin), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209803,209805,209806Orig1s000ClinPharmR.pdf."},{"key":"ref_47","unstructured":"FDA Center for Drug Evaluation and Research (2025, May 20). Integrated Review (Bexagliflozin), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/214373Orig1s000IntegratedR.pdf."},{"key":"ref_48","unstructured":"FDA Center for Drug Evaluation and Research (2025, May 20). Integrated Review (Sotagliflozin), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/216203Orig1s000IntegratedR.pdf."},{"key":"ref_49","unstructured":"Ministry of Food and Drug Safety, Astellas Pharma Korea (2005, February 02). Ipragliflozin [Package Insert]. Available online: https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetail?itemSeq=201404160."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/00498254.2016.1193913","article-title":"In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor","volume":"47","author":"Chino","year":"2017","journal-title":"Xenobiotica"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1124\/dmd.112.047258","article-title":"Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: Evidence from in vitro, human mass balance, and ketoconazole interaction studies","volume":"40","author":"Sigafoos","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100088","DOI":"10.1016\/j.obmed.2019.100088","article-title":"Clinical comparison of tofogliflozin and empagliflozin based on an analysis of 24-h accumulated urine in Japanese patients with type 2 diabetes mellitus","volume":"14","author":"Kobayashi","year":"2019","journal-title":"Obes. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Kim, M.-S., Song, Y.-K., Choi, J.-S., Ji, H.Y., Yang, E., Park, J.S., Kim, H.S., Kim, M.-J., Cho, I.-K., and Chung, S.-J. (2023). Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030942"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Choi, M.-K., Nam, S.J., Ji, H.-Y., Park, M.J., Choi, J.-S., and Song, I.-S. (2020). Comparative pharmacokinetics and pharmacodynamics of a novel sodium-glucose cotransporter 2 inhibitor, DWP16001, with dapagliflozin and ipragliflozin. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030268"},{"key":"ref_55","first-page":"364","article-title":"Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes","volume":"40","author":"Ndefo","year":"2015","journal-title":"Pharm. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s00044-024-03274-4","article-title":"Bexagliflozin: A comprehensive review of a recently approved SGLT2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"33","author":"Bassett","year":"2024","journal-title":"Med. Chem. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/BF01857622","article-title":"Effects of cardiovascular disease on pharmacokinetics","volume":"3","author":"Rodighiero","year":"1989","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1161\/CIRCULATIONAHA.115.020894","article-title":"Gastrointestinal and Liver Issues in Heart Failure","volume":"133","author":"Sundaram","year":"2016","journal-title":"Circulation"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bcp.13760","article-title":"The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: A critical appraisal of the evidence","volume":"85","author":"Mangoni","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bcp.15939","article-title":"Dapagliflozin pharmacokinetics is similar between patients with heart failure with reduced ejection fraction and patients with type 2 diabetes mellitus","volume":"90","author":"Melin","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1111\/bcp.16099","article-title":"Clinical pharmacokinetics and pharmacodynamics of empagliflozin in patients with heart failure","volume":"90","author":"Rascher","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"114663","DOI":"10.1016\/j.biopha.2023.114663","article-title":"In vivo assessment of the pharmacokinetic interactions between donafenib and dapagliflozin, donafenib and canagliflozin in rats","volume":"162","author":"He","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jchromb.2019.05.023","article-title":"A novel high-performance liquid chromatographic method combined with fluorescence detection for determination of ertugliflozin in rat plasma: Assessment of pharmacokinetic drug interaction potential of ertugliflozin with mefenamic acid and ketoconazole","volume":"1122","author":"Han","year":"2019","journal-title":"J. Chromatogr. B"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Cui, Y., Li, Y., Guo, C., Li, Y., Ma, Y., and Dong, Z. (2022). Pharmacokinetic interactions between canagliflozin and sorafenib or lenvatinib in rats. Molecules, 27.","DOI":"10.3390\/molecules27175419"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.29090\/psa.2023.01.22.304","article-title":"Study on consequences for interaction of myricetin with canagliflozin: A special attention to pharmacokinetics and pharmacodynamics of drug","volume":"50","author":"Kandukoori","year":"2023","journal-title":"Pharm. Sci. Asia"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"He, X., Li, Y., Ma, Y., Fu, Y., Xun, X., Cui, Y., and Dong, Z. (2022). Development of UPLC-MS\/MS method to study the pharmacokinetic interaction between sorafenib and dapagliflozin in rats. Molecules, 27.","DOI":"10.3390\/molecules27196190"},{"key":"ref_67","first-page":"498","article-title":"Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats","volume":"28","author":"He","year":"2023","journal-title":"Chinese J. Clin. Pharmacol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e5924","DOI":"10.1002\/bmc.5924","article-title":"Assessment of drug\u2013drug interaction of dapagliflozin with LCZ696 based on an LC\u2013MS\/MS method","volume":"38","author":"Wang","year":"2024","journal-title":"Biomed. Chromatogr."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"31201","DOI":"10.1039\/D3RA05929D","article-title":"A novel microextraction technique aided by air agitation using a natural hydrophobic deep eutectic solvent for the extraction of fluvastatin and empagliflozin from plasma samples: Application to pharmacokinetic and drug\u2013drug interaction study","volume":"13","author":"Alhazzani","year":"2023","journal-title":"RSC Adv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/jpp\/rgac022","article-title":"Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: A herb\u2013drug interaction study","volume":"74","author":"Nanjappan","year":"2022","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Abu Dayyih, W., Zakaraya, Z., Hailat, M., Al-Tawarah, N.M., Alkharabsheh, S., Nadher, H.K., Hailat, Z., Alarman, S.M., Khaleel, A., and Awad, R. (2024). The Validation and Determination of Empagliflozin Concentration in the Presence of Grapefruit Juice Using HPLC for Pharmacokinetic Applications. Molecules, 29.","DOI":"10.3390\/molecules29061236"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"485","DOI":"10.5530\/jyp.2023.15.64","article-title":"Impact of Sinapic acid on Ertugliflozin Pharmacokinetics and Pharmacodynamics in Type-2 Diabetic Rats","volume":"15","author":"Meesa","year":"2023","journal-title":"J. Young Pharm."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1124\/dmd.114.058305","article-title":"A Strategy for assessing potential drug-drug interactions of a concomitant agent against a drug absorbed via an intestinal transporter in humans","volume":"42","author":"Nakai","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/cpdd.166","article-title":"Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants","volume":"4","author":"Devineni","year":"2015","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1463-1326.2010.01314.x","article-title":"Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium\u2013glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects","volume":"13","author":"Kasichayanula","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/cpdd.472","article-title":"Assessment of the drug interaction potential of ertugliflozin with sitagliptin, metformin, glimepiride, or simvastatin in healthy subjects","volume":"8","author":"Dawra","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12325-015-0209-1","article-title":"Absence of Drug\u2013Drug Interactions Between Luseogliflozin, a Sodium\u2013Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males","volume":"32","author":"Sasaki","year":"2015","journal-title":"Adv. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.clinthera.2012.06.027","article-title":"Combination treatment with ipragliflozin and metformin: A randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus","volume":"34","author":"Veltkamp","year":"2012","journal-title":"Clin. Ther."},{"key":"ref_79","first-page":"74","article-title":"A pharmacokinetic\/pharmacodynamic drug\u2013drug interaction study of tofogliflozin (a new SGLT2 inhibitor) and selected anti-type 2 diabetes mellitus drugs","volume":"66","author":"Kasahara","year":"2016","journal-title":"Drug Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/bcp.15632","article-title":"Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium\u2013glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults","volume":"89","author":"Jeong","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/17425255.2023.2249397","article-title":"Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects","volume":"19","author":"Yoon","year":"2023","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3109\/00498254.2015.1113576","article-title":"Evaluation of drug\u2013drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males","volume":"46","author":"Wang","year":"2016","journal-title":"Xenobiotica"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1463-1326.2012.01624.x","article-title":"No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects","volume":"14","author":"Smulders","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/17425255.2015.982531","article-title":"Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers","volume":"11","author":"Kinoshita","year":"2015","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.clinthera.2016.07.005","article-title":"Lack of a pharmacokinetic interaction between saxagliptin and dapagliflozin in healthy subjects: A randomized crossover study","volume":"38","author":"Vakkalagadda","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/cts.13566","article-title":"Pharmacokinetic and pharmacodynamic drug\u2013drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers","volume":"16","author":"Kim","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12325-012-0055-3","article-title":"Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers","volume":"29","author":"Brand","year":"2012","journal-title":"Adv. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/17425255.2018.1418325","article-title":"Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes","volume":"14","author":"Rizos","year":"2018","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/bcp.15613","article-title":"Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium\u2013glucose cotransporter 2 inhibitor and metformin in healthy subjects","volume":"89","author":"Kim","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.clinthera.2015.05.002","article-title":"Pharmacokinetics of empagliflozin and pioglitazone after coadministration in healthy volunteers","volume":"37","author":"Macha","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.clinthera.2020.01.003","article-title":"Evaluation of the pharmacokinetic interaction between lobeglitazone and dapagliflozin at steady state","volume":"42","author":"Jang","year":"2020","journal-title":"Clin. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"59","DOI":"10.12793\/tcp.2023.31.e4","article-title":"Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects","volume":"31","author":"Kim","year":"2023","journal-title":"Transl. Clin. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.2147\/DDDT.S302215","article-title":"No Relevant Pharmacokinetic Drug\u2013Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-\u03b3 Agonist, in Healthy Subjects","volume":"15","author":"Kim","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/jcpt.13659","article-title":"No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium-glucose co-transporter 2 inhibitor and glimepiride in healthy Chinese male subjects","volume":"47","author":"Que","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_95","first-page":"S11","article-title":"Drug interaction study of ipragliflozin and migitol in healthy japanese subjects","volume":"91","author":"Nakajo","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clinthera.2014.01.003","article-title":"Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers","volume":"36","author":"Macha","year":"2014","journal-title":"Clin. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s13300-012-0016-5","article-title":"Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes","volume":"4","author":"Imamura","year":"2013","journal-title":"Diabetes Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"12565","DOI":"10.1038\/s41598-020-69228-z","article-title":"Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics","volume":"10","author":"Dyavar","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5414\/CP202158","article-title":"Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants","volume":"53","author":"Devineni","year":"2015","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/dom.12024","article-title":"Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin","volume":"15","author":"Kasichayanula","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.clinthera.2018.07.014","article-title":"Effect of rifampin on the pharmacokinetics of ertugliflozin in healthy subjects","volume":"40","author":"Dawra","year":"2018","journal-title":"Clin. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12325-011-0098-x","article-title":"Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin","volume":"29","author":"Kasichayanula","year":"2012","journal-title":"Adv. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.clinthera.2013.02.015","article-title":"Lack of clinically relevant drug\u2013drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers","volume":"35","author":"Macha","year":"2013","journal-title":"Clin. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clinthera.2014.12.018","article-title":"Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: A randomized, open-label, crossover study","volume":"37","author":"Heise","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e007046","DOI":"10.1161\/JAHA.117.007046","article-title":"Interaction between the sodium-glucose\u2013linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects","volume":"7","author":"Wilcox","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1002\/jssc.202200531","article-title":"Cytochrome P450 3A4-mediated pharmacokinetic interaction study between tadalafil and canagliflozin using high-performance thin-layer chromatography","volume":"45","author":"Ali","year":"2022","journal-title":"J. Sep. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.clinthera.2014.02.022","article-title":"Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants","volume":"36","author":"Devineni","year":"2014","journal-title":"Clin. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/dom.12028","article-title":"Lack of drug\u2013drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers","volume":"15","author":"Macha","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40261-013-0068-y","article-title":"Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers","volume":"33","author":"Macha","year":"2013","journal-title":"Clin. Drug Investig."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.clinthera.2023.06.002","article-title":"Pharmacokinetic and pharmacodynamic interactions between henagliflozin, a novel selective SGLT-2 inhibitor, and warfarin in healthy Chinese subjects","volume":"45","author":"He","year":"2023","journal-title":"Clin. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2147\/DDDT.S433377","article-title":"Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers","volume":"18","author":"Chen","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.clinthera.2022.06.001","article-title":"Evaluation of pharmacokinetic interactions between the new SGLT2 inhibitor SHR3824 and valsartan in healthy Chinese volunteers","volume":"44","author":"Huang","year":"2022","journal-title":"Clin. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1681\/ASN.20223311S1385c","article-title":"Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: Open-Label Drug-Drug Interaction Study in Healthy Adults: FR-PO217","volume":"33","author":"Chen","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/14779072.2023.2273900","article-title":"Adverse events and drug-drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure","volume":"21","author":"Finsterer","year":"2023","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/EDM-20-0017","article-title":"Myopathy secondary to empagliflozin therapy in type 2 diabetes","volume":"2020","author":"Gao","year":"2020","journal-title":"Endocrinol. Diabetes Metab. Case Reports"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/L20-0549","article-title":"Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report","volume":"173","author":"Brailovski","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.orcp.2019.08.001","article-title":"Chronopharmacology of dapagliflozin-induced antihyperglycemic effects in C57BL\/6J mice","volume":"13","author":"Yoshioka","year":"2019","journal-title":"Obes. Res. Clin. Pract."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Wang, D., Liu, J., Zhou, L., Zhang, Q., Li, M., and Xiao, X. (2022). Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.905171"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/12\/1604\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T05:13:59Z","timestamp":1765862039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/12\/1604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":118,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["pharmaceutics17121604"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17121604","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]}}}